The drug was tested in 137 ovarian cancer patients with the genetic mutation, with 34 percent having their tumors shrink or disappear for an average of 7.9 months. In a statement, Astra Zeneca said the approval strengthens its growing portfolio of cancer drugs and is good news for patients, "as currently the prognosis for ovarian cancer patients is poor and treatment options are progressively limited with each additional line of therapy." Side effects range from nausea, fatigue, diarrhea and distorted taste to less-common, more-serious problems including lung inflammation, a bone marrow cancer called acute myeloid leukemia and myelodysplastic syndrome, a disorder in which bone marrow can't produce enough functioning blood cells. Mark Capone, president of Myriad Genetic Laboratories, said in a statement that the diagnostic test "opens a new door in personalized medicine and represents a big step forward in tailoring treatment for women with ovarian cancer."